SCHEMBL30108895

SCHEMBL30108895

Cc1ccc(-c2nnc(N(C)[C@@H]3CCCNC3)c3ccccc23)c(O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 4/20 0.45
KCNH2 Q12809 7/20 0.44
CHEK1 O14757 2/20 0.44
RPLP1 P05386 5/20 0.36
RPLP0 P05388 5/20 0.36
RPS17 P08708 5/20 0.36
RPSA P08865 5/20 0.36
RPS2 P15880 5/20 0.36
RPL35A P18077 5/20 0.36
RPL7 P18124 5/20 0.36
RPL17 P18621 5/20 0.36
RPS4Y1 P22090 5/20 0.36
RPS3 P23396 5/20 0.36
RPS12 P25398 5/20 0.36
RPL13 P26373 5/20 0.36
RPL10 P27635 5/20 0.36
RPL12 P30050 5/20 0.36
RPL9; RPL9P7; RPL9P8; RPL9P9 P32969 5/20 0.36
RPL22 P35268 5/20 0.36
RPL4 P36578 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28934843 1.00 CHEK2 (0.45) CHEK2KCNH2CHEK1RPLP1RPLP0
SCHEMBL28934840 1.00 CHEK2 (0.45) CHEK2KCNH2CHEK1RPLP1RPLP0
SCHEMBL24840762 0.81 NLRP3 (0.51) NLRP3IL1B
SCHEMBL30108706 0.81 NLRP3 (0.51) NLRP3IL1B
SCHEMBL24840029 0.81 NLRP3 (0.51) NLRP3IL1B
SCHEMBL28934321 0.79 NLRP3 (0.41) NLRP3IL1B
SCHEMBL28934320 0.79 NLRP3 (0.41) NLRP3IL1B
SCHEMBL28934254 0.78 CHEK1 (0.42) CHEK2KCNH2CHEK1NLRP3ALOX5AP
SCHEMBL28934253 0.78 CHEK1 (0.42) CHEK2KCNH2CHEK1NLRP3ALOX5AP
SCHEMBL30108814 0.78 CHEK1 (0.42) CHEK2KCNH2CHEK1NLRP3ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294542-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2024-09-05 US disclosed
CN-115433163-A NLRP3 inflammasome inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2022-12-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294542-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF NLRP3, NLRP1, PYCARD CHEK2 4243/4885KCNH2 4090/4885CHEK1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.